New Hampshire 2026 Regular Session

New Hampshire House Bill HB1755

Introduced
12/17/25  

Caption

Relative to the 340B discounted drug purchasing program.

Impact

The introduction of HB1755 is set to considerably impact healthcare practices related to the 340B program in New Hampshire by fostering greater transparency and accountability among participating entities. By requiring detailed reporting on their financial operations and charitable activities, the bill aims to prevent potential abuses of the program, such as sending patients who are financially or medically indigent to collections. If the bill is enacted, compliance with these reporting requirements could reshape how 340B covered entities conduct their business, potentially altering their practices to ensure compliance and mitigate penalties.

Summary

HB1755 is a legislative proposal that aims to establish reporting requirements for entities participating in the 340B Discounted Drug Purchasing Program. It mandates that these entities provide annual financial and programmatic data to both the Department of Health and Human Services and the Department of Justice beginning in 2027. The information to be reported includes drug acquisition costs, payment amounts, charity care practices, and collection policies. The bill seeks to ensure that these entities operate in alignment with their charitable missions while utilizing the benefits of the 340B program.

Sentiment

Overall, the sentiment surrounding HB1755 appears to be mixed. Supporters advocate that the bill will promote fair use of the 340B program, protecting vulnerable patients and ensuring non-profit entities fulfill their charitable obligations. Critics, however, may argue that increased regulatory scrutiny could impede the operational flexibility of these entities or impose undue burdens that could divert resources away from patient care. The balance between enforcing accountability and allowing non-profits to operate effectively remains a focal point of the discussion.

Contention

Notable points of contention regarding HB1755 revolve around its implications for organizations that currently benefit from the 340B program. The penalties for non-compliance, which include fines for failing to report required data, invoke concerns about the financial viability of smaller entities that might struggle to meet the new requirements. Furthermore, the definition of charitable purpose and the criteria for determining whether an entity is operating as a for-profit business have raised concerns among stakeholders about the fairness and practicality of enforcement.

Companion Bills

No companion bills found.

Previously Filed As

NH SB253

Relative to participation in the federal 340B Drug Pricing Program.

NH SB264

Relative to the therapeutic cannabis program.

NH HB226

Relative to the use of drug checking equipment.

NH HB623

Relative to prohibiting corporations from purchasing single-family homes for a certain amount of time.

NH SB256

Relative to the affordability and safety of clinician administered drugs.

NH HB645

Relative to data collection and reporting requirements of the prescription drug affordability board.

NH SB297

Relative to pooled risk management programs.

NH SB234

Relative to the electric assistance program.

NH SB143

Relative to the impaired driver care management program and recovery residences.

NH HB126

Relative to prescriptions for certain controlled drugs.

Similar Bills

No similar bills found.